HU231414B1 - Tiadiazin származékok - Google Patents

Tiadiazin származékok Download PDF

Info

Publication number
HU231414B1
HU231414B1 HUP1800249A HUP1800249A HU231414B1 HU 231414 B1 HU231414 B1 HU 231414B1 HU P1800249 A HUP1800249 A HU P1800249A HU P1800249 A HUP1800249 A HU P1800249A HU 231414 B1 HU231414 B1 HU 231414B1
Authority
HU
Hungary
Prior art keywords
disorders
disorder
dioxo
trifluoromethyl
general formula
Prior art date
Application number
HUP1800249A
Other languages
English (en)
Hungarian (hu)
Inventor
István dr. Ledneczki
János dr. Éles
Pál dr. Tapolcsányi
Erzsébet dr. Jablonkai
Eszter Gábor
András dr. Visegrády
Zsolt dr. Némethy
György István dr. Lévay
József Levente Petró
György dr. Selényi
Original Assignee
Richter Gedeon Nyrt.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt. filed Critical Richter Gedeon Nyrt.
Priority to HUP1800249A priority Critical patent/HU231414B1/hu
Priority to TW108122604A priority patent/TWI827628B/zh
Priority to CN201980046660.4A priority patent/CN112424198A/zh
Priority to PE2021000052A priority patent/PE20210465A1/es
Priority to SG11202012769QA priority patent/SG11202012769QA/en
Priority to ARP190101992A priority patent/AR115783A1/es
Priority to CA3104264A priority patent/CA3104264A1/en
Priority to JP2021500540A priority patent/JP7440486B2/ja
Priority to US17/259,975 priority patent/US12194050B2/en
Priority to BR112020027016-4A priority patent/BR112020027016A2/pt
Priority to CU2020000109A priority patent/CU24622B1/es
Priority to MX2021000461A priority patent/MX2021000461A/es
Priority to MYPI2020006712A priority patent/MY207757A/en
Priority to GEAP201915558A priority patent/GEP20237459B/en
Priority to PCT/IB2019/055949 priority patent/WO2020012423A1/en
Priority to IL279939A priority patent/IL279939B2/en
Priority to EP19744869.9A priority patent/EP3820865A1/en
Priority to KR1020217004286A priority patent/KR20210033003A/ko
Priority to EA202190246A priority patent/EA202190246A1/ru
Priority to GEAP202215558A priority patent/GEAP202215558A/en
Priority to AU2019300515A priority patent/AU2019300515B2/en
Publication of HUP1800249A2 publication Critical patent/HUP1800249A2/hu
Priority to PH12021550007A priority patent/PH12021550007A1/en
Priority to CL2021000081A priority patent/CL2021000081A1/es
Priority to CONC2021/0001224A priority patent/CO2021001224A2/es
Publication of HU231414B1 publication Critical patent/HU231414B1/hu
Priority to JP2024020524A priority patent/JP2024056879A/ja
Priority to US18/947,529 priority patent/US20250064823A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D285/00Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/15Six-membered rings
    • C07D285/16Thiadiazines; Hydrogenated thiadiazines
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HUP1800249A 2018-07-13 2018-07-13 Tiadiazin származékok HU231414B1 (hu)

Priority Applications (26)

Application Number Priority Date Filing Date Title
HUP1800249A HU231414B1 (hu) 2018-07-13 2018-07-13 Tiadiazin származékok
TW108122604A TWI827628B (zh) 2018-07-13 2019-06-27 噻二(thiadiazine)衍生物
GEAP201915558A GEP20237459B (en) 2018-07-13 2019-07-12 Thiadiazine derivatives
IL279939A IL279939B2 (en) 2018-07-13 2019-07-12 Thiadiazine derivatives
SG11202012769QA SG11202012769QA (en) 2018-07-13 2019-07-12 Thiadiazine derivatives
ARP190101992A AR115783A1 (es) 2018-07-13 2019-07-12 DERIVADOS DE TIADIAZINAS, UN MÉTODO PARA SU PREPARACIÓN, COMPOSICIÓN Y COMBINACIÓN FARMACÉUTICA QUE LOS COMPRENDEN Y EL USO DE LOS MISMOS EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS AL RECEPTOR NICOTÍNICO DE ACETILCOLINA a7
CA3104264A CA3104264A1 (en) 2018-07-13 2019-07-12 Thiadiazine derivatives
JP2021500540A JP7440486B2 (ja) 2018-07-13 2019-07-12 チアジアジン誘導体
US17/259,975 US12194050B2 (en) 2018-07-13 2019-07-12 Thiadiazine derivatives
BR112020027016-4A BR112020027016A2 (pt) 2018-07-13 2019-07-12 Composto, uso de composto, método para tratamento ou prevenção de um transtorno associado à atividade de receptor nicotínico a7 de acetilcolina, composição farmacêutica, combinação, e, processo para a fabricação de compostos
CU2020000109A CU24622B1 (es) 2018-07-13 2019-07-12 Derivados de tiadiazina como moduladores del receptor nicotínico de acetilcolina alfa7
MX2021000461A MX2021000461A (es) 2018-07-13 2019-07-12 Derivados de tiadiazina.
MYPI2020006712A MY207757A (en) 2018-07-13 2019-07-12 Thiadiazine derivatives
CN201980046660.4A CN112424198A (zh) 2018-07-13 2019-07-12 噻二嗪衍生物
PCT/IB2019/055949 WO2020012423A1 (en) 2018-07-13 2019-07-12 Thiadiazine derivatives
PE2021000052A PE20210465A1 (es) 2018-07-13 2019-07-12 Derivados de tiadiazina
EP19744869.9A EP3820865A1 (en) 2018-07-13 2019-07-12 Thiadiazine derivatives
KR1020217004286A KR20210033003A (ko) 2018-07-13 2019-07-12 티아디아진 유도체
EA202190246A EA202190246A1 (ru) 2018-07-13 2019-07-12 Производные тиадиазина
GEAP202215558A GEAP202215558A (en) 2018-07-13 2019-07-12 Thiadiazine derivatives
AU2019300515A AU2019300515B2 (en) 2018-07-13 2019-07-12 Thiadiazine derivatives
PH12021550007A PH12021550007A1 (en) 2018-07-13 2021-01-04 Thiadiazine derivatives
CL2021000081A CL2021000081A1 (es) 2018-07-13 2021-01-12 Derivados de tiadiazina
CONC2021/0001224A CO2021001224A2 (es) 2018-07-13 2021-02-03 Derivados de tiadiazina
JP2024020524A JP2024056879A (ja) 2018-07-13 2024-02-14 チアジアジン誘導体
US18/947,529 US20250064823A1 (en) 2018-07-13 2024-11-14 Thiadiazine derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HUP1800249A HU231414B1 (hu) 2018-07-13 2018-07-13 Tiadiazin származékok

Publications (2)

Publication Number Publication Date
HUP1800249A2 HUP1800249A2 (en) 2020-01-28
HU231414B1 true HU231414B1 (hu) 2023-08-28

Family

ID=89992726

Family Applications (1)

Application Number Title Priority Date Filing Date
HUP1800249A HU231414B1 (hu) 2018-07-13 2018-07-13 Tiadiazin származékok

Country Status (23)

Country Link
US (2) US12194050B2 (https=)
EP (1) EP3820865A1 (https=)
JP (2) JP7440486B2 (https=)
KR (1) KR20210033003A (https=)
CN (1) CN112424198A (https=)
AR (1) AR115783A1 (https=)
AU (1) AU2019300515B2 (https=)
BR (1) BR112020027016A2 (https=)
CA (1) CA3104264A1 (https=)
CL (1) CL2021000081A1 (https=)
CO (1) CO2021001224A2 (https=)
CU (1) CU24622B1 (https=)
EA (1) EA202190246A1 (https=)
GE (2) GEAP202215558A (https=)
HU (1) HU231414B1 (https=)
IL (1) IL279939B2 (https=)
MX (1) MX2021000461A (https=)
MY (1) MY207757A (https=)
PE (1) PE20210465A1 (https=)
PH (1) PH12021550007A1 (https=)
SG (1) SG11202012769QA (https=)
TW (1) TWI827628B (https=)
WO (1) WO2020012423A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4103191A4 (en) * 2020-02-14 2024-03-06 University of Pittsburgh - of the Commonwealth System of Higher Education HEAT SHOCK PROTEIN MODULATORS AND THERAPEUTIC AGENTS FOR HUNTINGTON'S DISEASE
TWI901650B (zh) 2020-03-26 2025-10-21 匈牙利商羅特格登公司 啶及吡啶并〔3,4-c〕嗒衍生物
CN111454232B (zh) * 2020-05-30 2021-11-23 南方医科大学 一种1,3,4-噻二嗪类化合物及其应用
HU231691B1 (hu) 2021-09-29 2025-10-28 Richter Gedeon Nyrt GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006016548A1 (ja) 2004-08-09 2006-02-16 Eisai R & D Management Co., Ltd. ヘテロ環化合物を含有する新規な抗マラリア剤
NZ566036A (en) 2005-09-13 2010-06-25 Janssen Pharmaceutica Nv 2-Aniline-4-aryl substituted thiazole derivatives that modulate the alpha7 nicotinic receptor
ES2274729B1 (es) 2005-11-11 2008-06-01 Consejo Superior Investig. Cientificas Derivados de 5-carboxilato y 5-carboxamida 2-sustituidos de 1,1-dioxo-1,2,6-tiadiazina con propiedades cannabinoides.
US20100298314A1 (en) 2006-12-20 2010-11-25 Schering Corporation Novel jnk inhibitors
MX2010003155A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de ciclopropil aril amida y uso de los mismos.
MX2010003156A (es) 2007-10-04 2010-04-01 Hoffmann La Roche Derivados de aril amida substituida con tetrazol y usos de los mismos.
KR20100124272A (ko) 2008-02-07 2010-11-26 아보트 러보러터리즈 양성 알로스테릭 조절제로서의 아미드 유도체 및 이의 사용방법
AR070936A1 (es) 2008-03-19 2010-05-12 Janssen Pharmaceutica Nv 1,2,4 -triazoles trisustituidos
EP2110377A1 (en) 2008-04-15 2009-10-21 DAC S.r.l. Spirocyclic derivatives as histone deacetylase inhibitors
WO2009127678A1 (en) 2008-04-17 2009-10-22 Glaxo Group Limited Indoles as modulators of nicotinic acetylcholin receptor subtype alpha-71
JP5486591B2 (ja) 2008-05-09 2014-05-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ アセチルコリン受容体モジュレーターとしての三置換ピラゾール
CA2725940A1 (en) 2008-05-30 2009-12-23 Merck Sharp & Dohme Corp. Novel substituted azabenzoxazoles
EP2488520B1 (en) * 2009-10-13 2015-09-02 Merck Sharp & Dohme B.V. Condensed azine-derivatives for the treatment of diseases related to the acetylcholine receptor
EP3795573B1 (en) 2009-12-31 2022-07-06 Hutchison Medipharma Limited Certain triazolopyrazines, compositions thereof and methods of use therefor
WO2012042915A1 (en) 2010-10-01 2012-04-05 Raqualia Pharma Inc. Sulfamoyl benzoic acid heterobicyclic derivatives as trpm8 antagonists
SG192078A1 (en) * 2011-02-03 2013-08-30 Lupin Ltd Pyrrole derivatives used as modulators of alpha7 nachr
US9617210B2 (en) * 2013-03-13 2017-04-11 Lupin Limited Pyrrole derivatives as alpha 7 NACHR modulators
AR107928A1 (es) * 2016-03-22 2018-06-28 Merck Sharp & Dohme Moduladores alostéricos de receptores de acetilcolina nicotínicos
US10870630B2 (en) 2016-11-01 2020-12-22 Merck Sharp & Dohme Corp. Substituted bicyclic heteroaryl allosteric modulators of nicotinic acetylcholine receptors
WO2018112204A1 (en) 2016-12-14 2018-06-21 Cephalon, Inc. Spiropiperidine derivatives
SG11201908012SA (en) 2017-03-02 2019-09-27 Assembly Biosciences Inc Cyclic sulfamide compounds and methods of using same
HU231333B1 (hu) 2018-07-13 2023-01-28 Richter Gedeon Nyrt Spirokromán származékok

Also Published As

Publication number Publication date
CO2021001224A2 (es) 2021-02-17
HUP1800249A2 (en) 2020-01-28
US20210267993A1 (en) 2021-09-02
CA3104264A1 (en) 2020-01-16
US12194050B2 (en) 2025-01-14
IL279939A (en) 2021-03-01
IL279939B1 (en) 2024-09-01
BR112020027016A2 (pt) 2021-04-06
MX2021000461A (es) 2021-06-23
TWI827628B (zh) 2024-01-01
EA202190246A1 (ru) 2021-04-20
JP2024056879A (ja) 2024-04-23
CN112424198A (zh) 2021-02-26
WO2020012423A1 (en) 2020-01-16
CL2021000081A1 (es) 2021-10-29
EP3820865A1 (en) 2021-05-19
GEAP202215558A (en) 2022-07-25
PH12021550007A1 (en) 2021-09-20
CU20200109A7 (es) 2021-08-06
JP2021529813A (ja) 2021-11-04
AU2019300515B2 (en) 2025-01-23
SG11202012769QA (en) 2021-02-25
TW202019431A (zh) 2020-06-01
AU2019300515A1 (en) 2021-02-11
MY207757A (en) 2025-03-17
CU24622B1 (es) 2022-09-08
US20250064823A1 (en) 2025-02-27
KR20210033003A (ko) 2021-03-25
PE20210465A1 (es) 2021-03-08
AR115783A1 (es) 2021-02-24
GEP20237459B (en) 2023-01-25
JP7440486B2 (ja) 2024-02-28
IL279939B2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
JP5487214B2 (ja) キナーゼ阻害剤として有用なカルバゾールカルボキシアミド化合物
JP5363315B2 (ja) 新規ピペラジン、医薬組成物、およびその使用方法
US10723742B2 (en) Biphenyl compound or salt thereof
US20180098998A1 (en) Heterocyclic amides as kinase inhibitors
US20250064823A1 (en) Thiadiazine derivatives
EP3820869B1 (en) Spirochromane derivatives
TWI868079B (zh) 作為gabaa a5受體調節子的雙環衍生物
TW202017904A (zh) 經取代之(吖)吲哚衍生物
CA2813063A1 (en) Antagonist for mutated androgen receptor
JP2013540792A (ja) オレキシン受容体アンタゴニストとして有用なジアザ−スピロ[5.5]ウンデカン類
EA043926B1 (ru) Производные спирохромана
CN114671876A (zh) 新型茶碱类化合物、异构体或盐及其制备方法和用途
OA20785A (en) Thiadiazine derivatives
HK40044485B (en) Spirochromane derivatives
HK40044485A (en) Spirochromane derivatives
HK1253099B (en) Heterocyclic amides as kinase inhibitors